This post was originally published on this site
Biktarvy sales rose 18% to $2.2 billion, Descovy sales rose 4%, and Truvada sales declined 72% year-over-year in Q1.
The company expects Q2/22 EPS in the range of $6.20-$6.70, compared to the consensus of $6.50, and revenue in the range of $23.8-24.3 billion, compared to the consensus of $24.48 billion. The company sees product sales between $23.8 billion and $24.3 billion, which includes $2 billion in Veklury sales.
Shares of Gilead were down 15% year-to-date going into the earnings results.
By Davit Kirakosyan
